The cost of prescription drugs has always been a top issue for many employers and employees alike. With recent statements from President Donald Trump calling for a reduction in pricing and an increase in competition among drug companies, many in the healthcare industry are looking to value-based pricing as a way to alleviate cost.

To show businesses why certain drugs cost a particular price, PBMs have begun to share data with their clients to prove the effectiveness of certain drugs that deal with conditions such as oncology and inflammatory issues.

Register or login for access to this item and much more

All Employee Benefit News content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access